Welcome to our dedicated page for Braveheart Bio SEC filings (Ticker: BRVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Braveheart Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Braveheart Bio's regulatory disclosures and financial reporting.
Jiangsu Hengrui Pharmaceuticals Co., Ltd., a more-than-10% owner of Braveheart Bio, Inc., reported a conversion of its holdings. On 2026-08-07, it converted 32,500,000 shares of non-voting Series A preferred stock into 7,420,091 shares of common stock, consistent with terms that provide for automatic conversion immediately prior to the closing of Braveheart Bio’s initial public offering. Following the transactions, Jiangsu Hengrui directly holds 7,420,091 shares of common stock and no remaining shares of the non-voting Series A preferred stock.
Braveheart Bio, Inc. reported that investment entities affiliated with Forbion converted 75,000,000 shares of Series A Preferred Stock into 17,123,287 shares of Common Stock on August 7, 2026, in connection with the closing of the initial public offering, at a 1-for-4.38 conversion rate without additional consideration. On the same date, these Forbion entities also purchased 3,600,000 Common Shares at $18.00 per share in open-market or private transactions. Footnotes state that the management entities may be deemed to have voting and dispositive power over the fund holdings and that each reporting person disclaims Section 16 beneficial ownership except to the extent of its pecuniary interest.
Braveheart Bio, Inc. Chief Financial Officer Rickey James Paul purchased 27,777 shares of Common Stock on August 7, 2026 at $18.00 per share, bringing his directly held Common Stock to 520,927 shares. On August 5, 2026 he also received a stock option grant for 300,000 shares of Common Stock at an exercise price of $18.00 per share, expiring on August 4, 2036, with 1/48 of the option vesting monthly starting July 23, 2026, subject to continued service. Additional Common Stock is held indirectly through Rickey Trust CR and Rickey Trust BR, with 91,324 shares reported after the transaction for each trust; he disclaims beneficial ownership of those trust-held securities except to the extent of any pecuniary interest.
Braveheart Bio, Inc. director Lohoff Tim reported a grant of stock options on August 5, 2026. The award covers 30,000 Stock Options (Right to Buy) with an exercise price of $18.00 per share, expiring on August 4, 2036. These options, representing 30,000 underlying common shares, were acquired at a grant price of $0.00 and are held as direct ownership. According to the award terms, all shares underlying the option will vest in full on the earlier of August 5, 2027 or the date of the issuer's next annual stockholder meeting, conditioned on the reporting person's continued service to the company through that vesting date.
Braveheart Bio, Inc. reported that director and 10% owner Erez Chimovits received a grant of 30,000 stock options to acquire Braveheart Bio common stock at an exercise price of $18.00 per share. These options, which now total 30,000 derivative securities held directly, expire on August 4, 2036. The shares underlying the option will vest in full on the earlier of August 5, 2027 or the date of the company’s next annual stockholders’ meeting, subject to his continued service. Under a separate agreement, any securities or economic benefits from these options are to be transferred to OrbiMed Advisors LLC for the benefit of OrbiMed Private Investments IX, LP.
Braveheart Bio, Inc. director Christopher Viehbacher reported buying 83,333 shares of common stock at $18.00 per share on August 7, 2026, bringing his direct holdings to 609,519 shares. He also received a stock option for 30,000 shares at an exercise price of $18.00, expiring August 4, 2036; these options vest in full on the earlier of August 5, 2027 or the next annual stockholders’ meeting, subject to continued service. In addition, 150,338 shares are held indirectly through CAV FAMILY LLC, with beneficial ownership disclaimed except for any pecuniary interest.
Braveheart Bio, Inc. director David I. Malek reported two equity-related events. On August 7, 2026 he purchased 4,166 shares of Common Stock at $18.00 per share, bringing his directly held Common Stock to 533,845 shares. On August 5, 2026 he also received a grant of stock options for 30,000 shares of Common Stock with an exercise price of $18.00 per share, expiring on August 4, 2036; these options vest in full on the earlier of August 5, 2027 or the date of the company’s next annual stockholder meeting, subject to his continued service. In addition, 239,726 shares are reported as held indirectly by Malek Trust YM and 239,726 shares by Malek Trust NM, with beneficial ownership disclaimed except for any pecuniary interest.
Braveheart Bio, Inc. Chief Development Officer Michele A. Anderson reported two equity transactions. On August 7, 2026, she purchased 1,111 shares of Common Stock at $18.00 per share, bringing her direct holdings to 332,161 Common shares. On August 5, 2026, she received a grant of options for 300,000 shares of Common Stock at an exercise price of $18.00, expiring on August 4, 2036. According to the grant terms, 1/48th of the option shares vest in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to her continuous service with the company.
Braveheart Bio, Inc. CEO and President Murdoch Travis reported two insider transactions. On August 7, 2026, he purchased 83,333 shares of common stock at $18.00 per share, bringing his direct common stock holdings to 2,940,670 shares. On August 5, 2026, he received a grant of 550,000 stock options with an exercise price of $19.80 per share, expiring August 4, 2031; 1/48 of the options vest monthly starting July 23, 2026. Additional common shares are held indirectly through family trusts, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Braveheart Bio, Inc. director Jasper Bos received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $18.00 per share and expire on August 4, 2036. They vest in full on the earlier of August 5, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Bos holds 30,000 stock options directly.